Requisition update
RNS & Investor News
2024
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2023
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2022
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2021
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2020
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2019
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2018
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2017
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2016
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2015
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2014
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
2013
First products in Whole Foods Market Inc
09 August 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that GoFigure® meal replacement shakes and natural snack bars products are now available for sale in UK stores of the Whole Foods Market Inc, a large ($15bn turnover in 2015) American supermarket chain exclusively featuring healthy foods.
On 26 July 2016, OptiBiotix announced it had completed an investment to acquire 51% of The Healthy Weight Loss Company which produces GoFigure® products containing SlimBiome®, OptiBiotix's patented combination of natural ingredients, identified and developed by experts to support weight loss. The launch of SlimBiome® in the GoFigure® range establishes its use in food products with customer feedback consistently reporting reduced hunger, less snacking, and easier weight loss. GoFigure® products will initially be stocked in 8 UK Whole Foods Market Inc shops with opportunities for further expansion.
Stephen O'Hara, CEO of OptiBiotix, commented: "Following the success of our online launch we are delighted to have GoFigure products on the shelves in such a large and well known American supermarket chain. This is the first retail listing of GoFigure® products in the UK and we hope the precursor for future national and international listings. The listing expands the range of commercial opportunities for Slimbiome® both as a food or ingredient and dietary supplement."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 020 3713 4581 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Whole Foods Market Inc. is an American supermarket chain exclusively featuring foods without artificial preservatives, colors, flavors, sweeteners, and hydrogenated fats. As of 2015 it had 91,000 employees, $15.4bn revenue (2015), and 431 supermarkets in the United States, Canada, and the United Kingdom.
Latest RNS News
Latest Video
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023
www.proactiveinvestors.co.uk
Latest Podcast
Stephen OHara interview with Investors Champion
Stephen O'Hara | 04 Jul 2019
www.investorschampion.com